利妥昔单抗群体药代动力学研究进展

Research progress in population pharmacokinetics of rituximab

利妥昔单抗是一种人-鼠嵌合性单克隆抗体,目前在临床上联合化疗的治疗方案已成为治疗CD20+B细胞非霍奇金淋巴瘤的一线方案。此外也应用于一些自身免疫性疾病如类风湿关节炎、系统性红斑狼疮及免疫介导的肾病等。利妥昔单抗临床治疗效果显著,但药动学个体差异较大,为临床应用的有效性和安全性带来了一些不确定性,需要进行个体化治疗来提高其用药的合理性。目前,关于利用群体药代动力学方法优化利妥昔单抗给药方案的研究已有报道。本文通过查阅相关文献,对近年来利妥昔单抗群体药代动力学的研究进展进行综述,为国内患者制定利妥昔单抗个体化给药方案、实现精准化给药提供参考。

Rituximab,a chimeric human-mouse monoclonal antibody,has been used as a first-line treatment for CD20+B-cell non-Hodgkin lymphoma in combination with chemotherapy.It is also used for autoimmune diseases such as rheumatoid arthritis,systemic lupus erythematosus and immunemediated nephropathy.The clinical therapeutic effect of rituximab is significant.However,individual pharmacokinetics vary greatly,which bring some uncertainties to the efficacy and safety of clinical application,individualized treatment is needed to improve the rationality of its medication.Currently,studies on the optimization of rituximab administration regimen using population pharmacokinetics have been reported.Our paper reviewed the research progress in population pharmacokinetics of rituximab,aiming to provide reference to formulate an individualized dosing scheme of rituximab and realize precise administration for domestic patients.